VOICED : Acuerdo para facilitar el acceso mundial a la píldora anticovid de Pfizer

Pfizer has signed a voluntary license agreement to distribute its COVID-19 antiviral pill beyond wealthy countries, allowing generic manufacturers to supply the medication to 95 countries, covering 53% of the global population. The pill, developed with BioNTech, shows 89% efficacy in preventing severe COVID-19 outcomes. This move parallels Merck's similar agreement for its antiviral, Monlupiravir. Both treatments require a 10-dose regimen over five days and have minimal side effects.

What new insight or understanding did you gain from this video?